Edition:
United Kingdom

Michael Erman

J&J plans to test its COVID-19 vaccine in ages 12-18 soon

30 Oct 2020

NEW YORK Johnson & Johnson plans to start testing its experimental COVID-19 vaccine in youths aged 12 to 18 as soon as possible, and the company's previous experience with the same technology in a vaccine successfully used in children could give it a leg up with regulators.

Regeneron says its COVID-19 antibody treatment cut medical visits in trial

29 Oct 2020

Regeneron Pharmaceuticals Inc said on Wednesday its coronavirus antibody cocktail - the experimental treatment that U.S. President Donald Trump received - significantly reduced medical visits in a trial of nearly 800 patients with mild-to-moderate COVID-19.

Pfizer says no COVID-19 vaccine data yet, could be week or more before it reports

27 Oct 2020

Drugmaker Pfizer Inc said on Tuesday it does not yet have data from the late-stage trial of the COVID-19 vaccine it is developing with Germany's BioNTech SE , and provided a timeline that makes its release unlikely ahead of the Nov. 3 U.S. presidential election.Pfizer said there had not yet been enough infections in the 44,000-volunteer trial to trigger an analysis of whether or not the vaccine works. An independent panel will conduct the first analysis when it reaches 32 infections.

As COVID-19 cases spike, pneumonia vaccine demand rockets and Europe runs low

23 Oct 2020

MILAN/FRANKFURT/NEW YORK As COVID-19 infections rise, people seeking to avoid one lung disease compounding another are queuing up to get inoculated against bacterial pneumonia, causing shortages of a Merck & Co vaccine in parts of Europe.

Explainer: When will COVID-19 vaccines be generally available in the United States?

16 Oct 2020

U.S. President Donald Trump and the head of the Centers for Disease Control and Prevention (CDC) have disagreed about when a COVID-19 vaccine would become widely available. Trump has said enough vaccine would be available for every American by April, while the CDC director said vaccines were likely to reach the general public around mid-2021, an assessment more in line with most experts.

Pfizer says earliest U.S. filing for COVID-19 vaccine would be late November

16 Oct 2020

Pfizer Inc said on Friday it could file in late November for U.S. authorization of the COVID-19 vaccine it is developing, suggesting that a vaccine could potentially be available in the United States by the end of the year. | Video

World News